scholarly journals Study of Lipid Profile and Carcinoembryonic Antigen in Breast Cancer Patients

2020 ◽  
Vol 5 (1) ◽  
pp. 1-3
Author(s):  
Bushra Fiza ◽  
Maheep Sinha ◽  
Anjana Sharma ◽  
Shehreen Akhtar
Keyword(s):  
Breast Cancer ◽  
Lipid Profile ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Breast Cancer Patients

Serum Lipid Profile of Breast Cancer Patients

2009 ◽  
Vol 12 (4) ◽  
pp. 332-338 ◽  
Author(s):  
W.K.B.A. Owiredu ◽  
S. Donkor ◽  
B. Wiafe Adda ◽  
N. Amidu
Keyword(s):  
Breast Cancer ◽  
Lipid Profile ◽  
Cancer Patients ◽  
Serum Lipid ◽  
Serum Lipid Profile ◽  
Breast Cancer Patients

scholarly journals Assessment of cardiotoxicity in hormone positive postmenopausal breast cancer patients receiving aromatase inhibitors

2019 ◽  
Vol 9 (1) ◽  
pp. 11
Author(s):  
Reham M. Faheim ◽  
Eman A. El-Shaarawy ◽  
Dina A. Salem ◽  
Rehab G. Shaaban
Keyword(s):  
Breast Cancer ◽  
Blood Pressure ◽  
Lipid Profile ◽  
Cancer Patients ◽  
Aromatase Inhibitors ◽  
Hormone Receptor ◽  
Postmenopausal Breast Cancer ◽  
P Value ◽  
Breast Cancer Patients ◽  
Hormone Receptor Positive

Background: Aromatase inhibitors (AIs) represent an effective endocrine treatment for hormone receptor-positive postmenopausal breast cancer patients with early stage or metastatic disease.Objective: Assessment of Cardiotoxicity in Hormone positive Postmenopausal Breast Cancer Patients receiving AIs (upfront orswitch therapy).Methods: This cross sectional study included 123 postmenopausal breast cancer patients presented to the Clinical Oncology Department, Ain Shams University (Cairo, Egypt) in the interval from August 2016 to June 2017 with hormone receptor positive receiving Aromatase Inhibitors, To assess cardiotoxicity in these patients, they were subjected to blood pressure and lipid profile measurement, electrocardiography (ECG), and electrocardiography (ECHO) and classified into patients had Nolvadex then A.I (arm 1) and others had upfront A.I (arm 2).Results: The age of patients ranged from 41 years to 85 years with mean age of 61 years. Seventy one patients (57.7%) showed cardiotoxicity as assessed by ECHO. They showed significant correlation with rising age above 62 years, IHD, history of HTN and DM (p value: .001, .001, .017 and 0.035 respectively). However, correlation between cardiotoxity and blood pressure changes, lipid profile changes and ECG findings and ECHO changes in switch therapy and upfront A.I were not statistically significant (p value = .275, .116, .081 and .761 respectively).Conclusion: Assessment of cardiotoxicity in hormone positive postmenopausal breast cancer patients receiving Aromatase Inhibitors showed evidence of cardiotoxicity in half the patients (57.7%) as detected by ECHO only. They showed statistically non significant correlations either recievied switch therapy or upfront A.I.

Carcinoembryonic Antigen (CEA) in the Follow-Up of Disease-Free Breast Cancer Patients

1982 ◽  
Vol 68 (6) ◽  
pp. 477-480 ◽  
Author(s):  
Andrea Veronesi ◽  
Renato Talamini ◽  
Serenella Longhi ◽  
Diana Crivellari ◽  
Enzo Galligioni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Relapse Rate ◽  
Patient Population ◽  
Prognostic Value ◽  
Radical Mastectomy ◽  
Breast Cancer Patients ◽  
Disease Free

Carcinoembryonic antigen (CEA) assays (2536) were performed in 380 disease-free breast cancer patients after radical mastectomy. In the 334 evaluable patients with 3 or more determinations, the overall relapse rate after a median follow-up of 29 months was 11 %. Of 203 patients with normal CEA values, 19 (9.3 %) relapsed. In the 50 patients with the highest CEA value greater than 20 ng/ml, the relapse rate was 26 %; in the 12 patients with gradually increasing CEA elevations it was 50 %. However, CEA was unable to predict recurrence in N- patients. Premastectomy N+ was significantly associated with greater than 20 ng/ml or gradually increasing CEA values, suggesting the lack of an independent prognostic value of CEA in our patient population.

scholarly journals Diagnostic usefulness of serum carcinoembryonic antigen determinations in breast cancer patients

2003 ◽  
Vol 3 (2) ◽  
pp. 30-34
Author(s):  
Zlata Mujagić ◽  
Hamza Mujagić
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Sensitivity And Specificity ◽  
Tumour Marker ◽  
Breast Cancer Patients ◽  
Female Patients ◽  
Healthy Women ◽  
Serum Carcinoembryonic Antigen ◽  
Circulating Levels

Background and purpose: Carcinoembryonic antigen (CEA) is used as a tumour marker in breast cancer (BC). In order to assess diagnostic value of CEA in BC we examined its serum levels and frequencies of its increase in breast cancer patients (BCP), and compared them to those in controls. We also determined CEA in patients with metastatic and non-metastatic BC, and calculated sensitivity and specificity of CEA in BC.Patients and methods: The main experimental group consisted of 47 female patients with histologically proved diagnosis of BC. There were two control groups: clinically healthy women, and female patients with other locations of cancer. Circulating levels of CEA were measured by means of immunoradiometric assay. Results were processed by means of t-test and two-way analysis of variance.Results: Circulating levels of CEA, before treatment in BCP, were significantly higher (p<0.0001) than in healthy women, and in patients with other cancers (p<0.007), while serum CEA in other cancer patients was significantly higher (p<0.01) than in healthy control. There was a difference between frequencies of CEA increase in BCP and healthy women, while such a difference did not exist between BCP and other cancer patients. The circulating levels of CEA in metastatic BCP were significantly higher (p<0.03) in comparison to non-metastatic patients. Sensitivity and specificity of CEA in BCP was 65.0%, and 57.1%, respectively.Conclusions: CEA does not have high tumour specificity for BC, since its circulating levels as well as frequencies of its increase may be elevated in patients with other types and locations of cancer, different from breast cancer. CEA can be detected in the serum of majority of patients with metastatic BC. CEA may be used as prognostic tumour marker in advanced BC.

scholarly journals Assessment of Estradiol, Progesterone and Lipid Profile among Breast Cancer Patients in Ethiopia: Hospital-based Comparative Cross-Sectional Study

2021 ◽  
Author(s):  
Etagegn Tadesse ◽  
Daniel Seifu ◽  
Menakath Menon ◽  
Wondmagegnehu Tigeneh ◽  
Teka Obsa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lipid Profile ◽  
Cancer Patients ◽  
Cross Sectional Study ◽  
Healthy Controls ◽  
Breast Cancer Patients ◽  
Sectional Study ◽  
Serum Progesterone ◽  
Cross Sectional ◽  
Progesterone Metabolism

Abstract Background Breast cancer is the most often diagnosed type of cancer and the leading cause of death worldwide. Estrogen, also known as estradiol, influences progesterone metabolism and modifies lipid metabolism. Thus, steroid hormone and lipid profile levels for breast cancer patients must be evaluated. However, this has yet to be explored and used for therapy in Ethiopia. As a result, the present study at Tikur Anbessa Specialized Hospital attempted to assess serum estrogen, progesterone, and lipid profile levels in breast cancer patients and healthy controls. Methods A hospital-based comparative cross-sectional study was conducted on a total of 80 participants (40 newly diagnosed breast cancer patients and 40 healthy control females). A convenient sampling method was used to recruit the study participants. Steroid hormones and lipid profile were determined using immunoassays and an enzymatic colorimetric technique, respectively. SPSS version 20.0 was used for statistical analysis, and p-values of 0.05 were considered statistically significant. Results When compared to healthy controls, the mean serum progesterone, TC, and HDL-C levels in breast cancer patients were considerably lower, while estradiol, TG, and LDL-C levels were insignificantly higher. Conclusions Breast cancer may be to blame for changes in progesterone, estradiol, and lipid profile levels, which can lead to secondary problems.

Sign in / Sign up

Export Citation Format

Share Document